Karyopharm Therapeutics Inc. (NASDAQ:KPTI) will announce its earnings results before the market opens on Thursday, November 2nd. Analysts expect the company to announce earnings of ($0.64) per share for the quarter.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. Karyopharm Therapeutics’s revenue for the quarter was down 95.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.84) earnings per share. On average, analysts expect Karyopharm Therapeutics to post $-2.65 EPS for the current fiscal year and $-2.11 EPS for the next fiscal year.

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded down 1.17% during mid-day trading on Tuesday, reaching $10.10. The company’s stock had a trading volume of 43,565 shares. The firm has a 50-day moving average of $10.97 and a 200-day moving average of $9.80. The firm’s market capitalization is $476.09 million. Karyopharm Therapeutics Inc. has a 52 week low of $6.27 and a 52 week high of $14.63.

In other Karyopharm Therapeutics news, Director Mansoor Raza Mirza sold 2,882 shares of the firm’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $11.00, for a total value of $31,702.00. Following the transaction, the director now owns 2,882 shares of the company’s stock, valued at $31,702. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 10,695 shares of company stock worth $118,950 in the last ninety days. Corporate insiders own 14.71% of the company’s stock.

A number of research firms have weighed in on KPTI. Canaccord Genuity set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 8th. BidaskClub raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “buy” rating and set a $19.00 price target (up previously from $16.00) on shares of Karyopharm Therapeutics in a research report on Thursday, August 10th. ValuEngine cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 18th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $18.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, September 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $15.38.

ILLEGAL ACTIVITY WARNING: This news story was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://theolympiareport.com/2017/10/31/karyopharm-therapeutics-inc-kpti-set-to-announce-quarterly-earnings-on-thursday.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.